Lupin on Tuesday announced the launch of Ethacrynic Acid tablets USP after receiving an approval from the United States Food and Drug Administration (USFDA) earlier.
The company said that the product would be manufactured at Lupin's Nagpur OSD facility, in India. Ethacrynic Acid tablets, a generic equivalent of Edecrin tablets, are indicated for the treatment of edema when an agent with greater diuretic potential than those commonly employed is required. The tablet is mainly used in treatment of the edema associated with congestive heart failure, cirrhosis of the liver and renal disease. It is also indicated for short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease.According to IQVIA, Ethacrynic Acid tablets USP had annual sales of approximately $20 million in the US.
Shares of Lupin were up 0.17% at Rs 674.40. The stock has tumbled 13.68% in last three months as compared to a 2.22% fall in benchmark Nifty 50 index.
Lupin is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The firm offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas.
On a consolidated basis, Lupin reported net loss of Rs 835 crore in Q3 December 2019 as against net loss of Rs 151.75 crore in Q3 December 2018. Net sales declined 2.75% to Rs 3716.09 crore in Q3 December 2019 over Q3 December 2018.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
